Vimta Labs Ltd

- As of the latest update in the call (Q2 FY25), Vimta Labs does not have any current plans for fundraising through equity or preferential issues. - Harita Vasireddi explicitly mentioned: "As of now, we don't have any thought in that direction" regarding fundraising. - On the debt side, the company maintains a net debt-free balance sheet with total debt of INR116 million and a low debt-to-equity ratio (0.03x) as of September 30, 2024. - Capex is ongoing with guidance of INR90 crores for FY25, mostly funded internally or through existing arrangements. - Future fundraising needs have not been indicated; the company appears comfortable with current financial resources and capex plans.

- Vimta Labs has placed an order for a second chamber for the electronics business, expected to be delivered in late Q4 or early Q1. - Total infrastructure-related capex is around INR 70 crores, expected to be capitalized during Q3, with the majority already spent last year. - Additional capex of INR 50-60 crores is planned, with nearly that amount already incurred in H1 FY25. - Total capex guidance for FY25 remains around INR 90 crores. - Expansion plans include adding one more EMI/EMC chamber for the electronics segment due to 80-85% current utilization, with a long lead time for installation. - No current plans for preferential equity or fundraising. - The company is creating new facilities to house food testing and preclinical services, with significant ongoing investments.

- Company targets INR 500 crores run rate revenue by FY26, aiming for INR125 crores quarterly run rate by Q3/Q4 of next year. - Growth primarily driven by the pharmaceutical segment, including preclinical, clinical research, and analytical services. - Food testing segment faced temporary setbacks due to lab relocations but expected to stabilize. - Electronics testing business expanding with a new EMI/EMC chamber ordered, expected operational by late Q4 or early next year. - Export revenue currently 25-30%, expected to remain steady; expansion has no direct link to export growth. - Capacity expansions and new facility commercialization from Q3 FY25 will support incremental volume growth (30-40% increase anticipated in some segments). - Potential partnerships and new contracts arising from regulatory shifts (e.g., BIOSECURITY Act) may further boost volumes in the coming years.

- Vimta Labs aims to reach a revenue run rate of INR 500 crores in FY '26, up from about INR 85 crores quarterly currently. - EBITDA margins are sustainable around current mid-30% levels, expected to maintain with capacity additions planned. - Incremental revenue growth expected primarily from the pharmaceutical segment, which remains the dominant business. - New life sciences facility and clinical trial services are key growth drivers contributing to improved revenues. - Electronics business is expanding with an additional EMI/EMC chamber ordered to meet increasing demand. - Preclinical and analytical segments within pharma are poised for growth, supported by complex generic studies and global client base. - Capex of around INR 90 crores planned for FY '25 to support infrastructure and capacity expansion. - Profit after tax and EPS have shown strong YoY growth, with PAT margins around 20% in Q2 FY '25. - Company expects gradual revenue growth with operational leverage kicking in post capacity ramp-up.

- An order has been placed for a second EMI/EMC chamber for the electronics business. - Delivery of this chamber is expected in late Q4 or early Q1. - Existing chamber capacities are currently utilized around 80% to 85%. - No specific details on the overall current order book size or pending orders were disclosed. - The management is proactively expanding capacity to accommodate anticipated growth without slowdown. - There are ongoing contracts in the biosimilar and clinical trial segments, including preclinical and analytical services. - Partnership discussions with major U.S. innovator companies are in early stages, mainly for cost-cutting related offshoring work. - No definite updates on large order inflows related to the BIOSECURE Act yet, but some active discussions with major players are expected to mature by early next year.